Back to News
Market Impact: 0.3
Nicox Partner Ocumension's NCX 470 NDA Accepted For Review In China For Glaucoma
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Nicox announced that China’s NMPA accepted the New Drug Application for NCX 470 for review, following submission by its exclusive China licensee Ocumension Therapeutics. The acceptance advances NCX 470 through the Chinese regulatory pathway, but approval timing and commercial impact remain uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALCOX0.55
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- US legislators push AI safety laws amid human extinction warnings
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports